This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	DNA; topoisomerase II (TOP2)	<p>Studies in mice suggest that pentyl PABC-Doxaz, a pentyl carbamate derivative of doxazolidine, could be useful for treating cancer and could have fewer side effects than doxorubicin and irinotecan. In mouse xenograft models of human liver and non-small cell lung cancer (NSCLC), pentyl PABC-Doxaz reduced tumor proliferation compared with vehicle and showed less toxicity than doxorubicin. Tissue analysis showed that the compound had lower cardiotoxicity and nephrotoxicity than doxorubicin and did not cause visible damage to gastrointestinal tissues, which can occur with irinotecan. Next steps include evaluating the compound in additional safety, efficacy and pharmacological studies and improving the formulation and method of delivery.</p> <p>SciBX 2(30); doi:10.1038/scibx.2009.1172 Published online Aug. 6, 2009</p>	Patent application filed covering composition of matter and use in treatment of cancer; available for licensing from the University of Colorado Office of Technology Transfer	<p>Barthel, B.L. <i>et al. J. Med. Chem.</i>; published online July 27, 2009; doi:10.1021/jm900694z</p> <p>Contact: Tad H. Koch, University of Colorado Denver Health Sciences Center, Aurora, Colo. e-mail: tad.koch@colorado.edu</p>